* Champions Oncology Inc is expected to show a rise in quarterly revenue when it reports results on December 11 for the period ending October 31 2024
* The Hackensack New Jersey-based company is expected to report a 12.8% increase in revenue to $13.054 million from $11.57 million a year ago, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for Champions Oncology Inc is for earnings of 1 cent per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Champions Oncology Inc is $6.00, above its last closing price of $4.34.
This summary was machine generated December 6 at 21:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments